financetom
Business
financetom
/
Business
/
Cadence Design Systems Q4 Earnings: Revenue Beat, EPS Beat, 'Very Well Positioned' To Benefit From AI, Shares Slide On Soft Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cadence Design Systems Q4 Earnings: Revenue Beat, EPS Beat, 'Very Well Positioned' To Benefit From AI, Shares Slide On Soft Guidance
Feb 18, 2025 2:08 PM

Cadence Design Systems Inc ( CDNS ) reported fourth-quarter financial results and issued soft guidance after the bell. Here’s a rundown of the report.

Q4 Revenue: $1.36 billion, versus estimates of $1.35 billion

Q4 Adjusted EPS: $1.88, versus estimates of $1.82

Total revenue was up about 27% year-over-year in the fourth quarter. The company ended the quarter with a record backlog of $6.8 billion and current remaining performance obligations of $3.4 billion. Cadence said it had $2.64 billion in cash and cash equivalents at quarter’s end.

“Our momentum continues to build as we exited 2024 with record bookings and record backlog. Cadence is very well positioned to benefit from the various phases of AI, including the current AI infrastructure buildout, applying AI to our own products, and expanding into new markets such as life sciences,” said Anirudh Devgan, president and CEO of Cadence Design Systems ( CDNS ).

Check This Out: Bumble Shares Drop After Q4 Report: Here’s Why

Outlook: Cadence Design Systems ( CDNS ) expects full-year 2025 revenue to be in the range of $5.14 billion to $5.22 billion versus estimates of $5.25 billion. The company anticipates full-year adjusted earnings of $6.65 to $6.75 per share versus estimates of $6.83 per share, per Benzinga Pro.

Management will further discuss the company’s quarterly results on a conference call scheduled for 5 p.m. ET.

CDNS Price Action: Cadence Design Systems ( CDNS ) shares were down 4.64% after hours, trading at $286.50 at the time of publication Tuesday, according to Benzinga Pro.

Read Next:

Warren Buffett Unfazed By Trump’s Tariff Threats: Oracle Of Omaha Bets On Mexico, Beer

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Why Spirit Airlines Stock Is Taking Off Monday
Why Spirit Airlines Stock Is Taking Off Monday
Oct 21, 2024
Spirit Airlines Inc ( SAVE ) shares are trading higher Monday after the company extended its debt refinancing deadline. What To Know: Spirit Airlines ( SAVE ) on Friday announced that it reached an agreement with the U.S. Bank National Association to extend its existing credit card processing agreement to Dec. 23. The deadline was previously set to expire on Monday....
Beyond to Invest $25 Million in Kirkland's Under Strategic Partnership
Beyond to Invest $25 Million in Kirkland's Under Strategic Partnership
Oct 21, 2024
11:23 AM EDT, 10/21/2024 (MT Newswires) -- Kirkland's (KIRK) and Beyond (BYON) said Monday they have formed a partnership under which Beyond will invest $25 million in Kirkland's in a combined debt and equity transaction. Kirkland's entered into a $17 million term loan credit agreement with Beyond, of which $8.5 million comprises of a convertible note that will convert into...
Disney Taps Morgan Stanley Chair to Lead Board, Plans to Name New CEO in 'Early 2026'
Disney Taps Morgan Stanley Chair to Lead Board, Plans to Name New CEO in 'Early 2026'
Oct 21, 2024
11:24 AM EDT, 10/21/2024 (MT Newswires) -- Walt Disney ( DIS ) said Monday it appointed current Morgan Stanley ( MS ) Executive Chairman James Gorman as its board chair, and that it will announce Chief Executive Bob Iger's replacement early in 2026. As previously announced, Gorman is set to step down from his role at Morgan Stanley ( MS...
Trevi Therapeutics Completes Enrollment for Phase 2a Trial of Refractory Chronic Cough Treatment; Shares Rise
Trevi Therapeutics Completes Enrollment for Phase 2a Trial of Refractory Chronic Cough Treatment; Shares Rise
Oct 21, 2024
11:20 AM EDT, 10/21/2024 (MT Newswires) -- Trevi Therapeutics ( TRVI ) said Monday it has completed enrollment in its phase 2a trial to evaluate the efficacy, safety, tolerability and dosing of its experimental Haduvio treatment for refractory chronic cough. The company expects to report topline data in Q1 of 2025. Trevi shares were up nearly 5% in recent trading....
Copyright 2023-2026 - www.financetom.com All Rights Reserved